Αρχική World News FDA Approves Second CAR T-Cell Therapy for Lymphoma

FDA Approves Second CAR T-Cell Therapy for Lymphoma

May 22, 2018, by NCI Staff

For tisagenlecleucel, T cells are engineered to target cells that express CD19, such as lymphoma cells (malignant B cells).

Credit: Adapted from J Hematol Oncol September 2014. doi: 10.1186/s13045-014-0058-4. CC BY 4.0.

UPDATE: More recent results from the clinical trial that led to this FDA approval were published December 1, 2018, in the New England Journal of Medicine. This post has been updated to reflect the most recent findings.

On May 1, 2018, the Food and Drug Administration (FDA) approved the CAR T-cell therapy tisagenlecleucel (Kymriah) for adults with certain types of non-Hodgkin lymphoma, making it the second CAR T-cell therapy approved for lymphoma and the second FDA approval for this drug.

Last year, FDA approved another CAR T-cell therapy, axicabtagene ciloleucel (Yescarta), for the treatment of diffuse large B-cell lymphoma (DLBCL). CAR T-cell therapy is a type of immunotherapy that involves a one-time infusion of a patient’s own immune cells that have been genetically modified to recognize and attack cancer. Both tisagenlecleucel and axicabtagene ciloleucel target cells—both cancerous and normal—that express a molecule called CD19 on their surfaces.

Tisagenlecleucel was the first CAR T-cell therapy to receive FDA approval. It was approved in 2017 for the treatment of children and young adults with leukemia.

The new approval of tisagenlecleucel is for lymphoma—specifically DLBCL, high-grade B-cell lymphoma, and DLBCL that arises from follicular lymphoma—that has come back or gotten worse after prior treatment.

Tisagenlecleucel “definitely fills an important niche,” said Wyndham Wilson, M.D., Ph.D., head of the Lymphoma Therapeutics Section of NCI’s Center for Cancer Research. “But its impact, at least to begin with, will be limited” because the treatment is completely personalized and available only at certain cancer centers, Dr. Wilson added.

About 60% to 70% of people with DLBCL have lasting responses to their initial therapy. For people whose DLBCL does not respond (refractory disease) or comes back (relapses) after initial treatment, “the ability to cure [these patients] with conventional therapy is very, very limited,” Dr. Wilson explained.

Likewise, DLBCL that arises from follicular lymphoma can be hard to treat and the long-term prognosis for some of these patients is poor. Follicular lymphoma can sometimes transform into DLBCL after patients receive treatment for follicular lymphoma.

FDA’s new approval makes available another CAR T-cell therapy that “is likely to cure some patients [with DLBCL] who wouldn’t be cured with other available strategies,” Dr. Wilson said.

The JULIET Trial

The new approval was based on results from a phase 2 clinical trial, called JULIET, for people with relapsed or refractory DLBCL who previously had at least two systemic cancer treatments or a stem cell transplant. Novartis, the manufacturer of tisagenlecleucel, sponsored the trial.

Study participants received chemotherapy to eliminate their existing immune cells before receiving a single infusion of tisagenlecleucel.

Of the trial participants who could be evaluated, half had a response. Overall, 18% had a partial response, meaning their tumors shrank but not completely, and about one third of participants had a complete response, meaning all signs of the cancer disappeared. Complete responses lasted longer than partial responses.

Study participants need to be followed for a longer period to determine how long their responses last, Dr. Wilson noted.

Nearly 60% of trial participants experienced an inflammatory reaction known as cytokine release syndrome (CRS), a known side effect of CAR T-cell therapy, with 22% judged to have more severe CRS. And 21% of patients had a neurological event, another common side effect of CAR T-cell therapy.

“These things can be managed, and we’re learning more about how to do that,” Dr. Wilson explained. “But that doesn’t mean they can’t be severe or life-threatening for some patients.”

FDA approved tisagenlecleucel with a Risk Evaluation and Mitigation Strategy, a drug safety program intended to help reduce the occurrence and severity of treatment side effects like CRS and neurological toxicity. Under the program, health care providers at facilities where tisagenlecleucel is offered must be specially trained to monitor and manage these side effects.

Other common side effects of tisagenlecleucel included infection, fever, low blood cell counts, and diarrhea.

In addition to the potential side effects, tisagenlecleucel is limited in several ways, Dr. Wilson pointed out. Not all people with DLBCL are eligible to receive the treatment or have access to one of the certified treatment centers. And it provides lasting benefits to only a minority of patients.

With FDA’s new approval, eligible patients with DLBCL now have two options for CAR T-cell therapy. For tisagenlecleucel and axicabtagene ciloleucel, the patient’s immune cells are modified in the same way. And the cost of both therapies is about the same. The only way to determine which of the two therapies is more effective would be to compare them head-to-head in a clinical trial, noted Dr. Wilson.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung Cancer, Breast Cancer, and Sarcoma

In the annual Research Round Up series, Cancer.Net Associate Editors answer the question, “What was the most exciting or practice-changing research in your field...

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

The right combination for early detection

The upcoming Early Detection of Cancer Conference brings together experts from multiple disciplines to share ground breaking research and progress in the field. Here...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...